Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

Prominent Among Global Pioneers

 
• By Dexter Jie Yan
  
Antibody-drug conjugates are increasingly being studied in combination with PD-(L)1/VEGF-directed bispecific antibodies worldwide, with Chinese companies prominent among the pioneers. (Shutterstock)

More from Clinical Trials

More from R&D